This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. By the numbers Q1 revenue: 4.1 billion euros 2% decrease year-over-year Q1 net income: 72 million euros Compared to net loss of 998 million euros in Q1 2024 Philips has predicted tariffs will have a net impact of up to 300 million euros ($340 million) this year despite the company taking “substantial” steps to mitigate the effects. The prediction, which Philips made in its first-quarter earnings Tuesday, led the company to lower its forecast full-year margin range by one percentage point. Philips is assuming bilateral U.S.-China tariffs stay in place and paused U.S. tariffs on other countries resume. The forecast excludes the potential wider economic impacts of tariffs and trade tensions. Tariffs between the U.S. and China account for most of the impact, Philips CFO Charlotte Hanneman said on an earnings call with investors. Philips expects that tariffs will have a “more pronounced effect in the second half of the year,” Hanneman said, and the diagnosis and treatment and personal health units will be more affected than the connected care business. Hanneman said Philips is trying to limit the impact of tariffs by “optimizing network flexibility, effective inventory management, pursuing exceptions [and] selective pricing.” CEO Roy Jakobs shared more details about how Philips is changing its manufacturing network to soften the blow, explaining that the current situation requires the company to accelerate the localization of production in the U.S. “We are leveraging our current footprint to expand. That's the fastest way we can mitigate, given the approval cycles and the regulatory processes, because you have then the quality management systems in place that you can use,” Jakobs said. “We have a strong footprint that we will leverage for the max to kind of ensure we can do it with speed and also with lower cost and lower capital requirements.” The program will build on existing efforts to localize production. Manufacturing in China is already 90% localized, Jakobs said, and Philips is pursuing Europe for Europe and Americas for America policies. The efforts are intended to dull the impact of tariffs in 2025 and beyond, with Hanneman predicting that the benefits of the actions will increase over time. China challenges continue Philips provided an update on its performance in China, which has dragged on the company’s results in recent quarters. Double-digit drops in sales across all Philips’ businesses in China caused comparable revenues to fall 2% in the quarter. Philips also reported a drop in orders in China. Story Continues The company’s struggles in China began in the second half of 2024 and, as such, the second half of 2025 will benefit from easier comparisons to the prior year. However, while Philips expects growth to improve because of the easier comparisons, Hanneman said the company is “not betting on a rebound” in the country in the second half of 2025 and is taking a cautious view of the market for the rest of the year. Recommended Reading Philips expects sales struggles in China to continue in 2025 View Comments
Philips cuts earnings forecast after calculating $340M tariff hit
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...